// App-Quantinova.ai

5040 : A phaseII multicenter biomarker trial to study the predictive value of TMPRSS2-ERG before enzalutamide treatment in chemo-nave metastatic castration-resistant prostate cancer.

Researchers

Presenter

  • Enrique Grande

Principal Investigators

  • Daniel Wetterskog

  • Albert Font Pous

  • Sergio Vazquez-Estevez

  • Aranzazu Gonzalez del Alba

  • Begona Mellado

  • Ovidio Fernandez Calvo

  • Maria Jose Mendez-Vidal

  • Miguel Angel Climent

  • Ignacio Duran

  • Enrique Gallardo Diaz

  • Angel Rodriguez Sanchez

  • Carmen Santander

  • M Isabel Saez

  • Javier Puente

  • Elena Castro

  • Daniel E. Castellano

  • Gerhardt Attard

  • Enrique Gonzalez-Billalabeitia

Medical Centers

  • GEICO & MD Anderson Cancer Center Madrid, Madrid, Spain

  • Department of Hematology and Medical Oncology, Hospital G. Universitario Morales Meseguer, IMIB-Arrixaca, Universidad Catolica San Antonio, Murcia, Spain

  • UCL Cancer Institute, United Kingdom

  • Institut Catala d'Oncologia, Hospital Universitario German Trias i Pujol, Badalona, Spain

  • Lucus Augusti University Hospital, Lugo, Spain

  • Hospital Universitario Son Espases, Palma de Mallorca, Spain

  • Hospital Clinic de Barcelona. Universitat de Barcelona, Barcelona, Spain

  • Complexo Universitario de Ourense, Ourense, Spain

  • Reina Sofia University Hospital, Cordoba, Spain

  • Instiuto Valenciano de Oncologia, Valencia, Spain

  • Department of Radiology, H. Universitario Marques de Valdecilla, Santander, Spain

  • Hospital Universitari Parc Tauli, Barcelona, Spain

  • Hospital of Leon, Leon, Spain

  • H. Universitario Miguel Servet, Zaragoza, Spain

  • CRIS Cancer Foundation Prostate Cancer Research Group, Institute of Biomedical Research in Malaga/ CNIO-IBIMA Genitourinary Cancer Research Unit, H Universitarios Virgen de la Victoria y Regional de Malaga, Malaga, Spain

  • Hospital Universitario Clinico San Carlos, Madrid, Spain

  • CNIO - Spanish National Cancer Research Center, Madrid, Spain

  • Medical Oncology Service, Hospital Universitario 12 de Octubre, Madrid, Spain

  • The Institute of Cancer Research & The Royal Marsden, London, Spain

  • Department of Hematology and Medical Oncology, Hospital Universitario Morales Meseguer, Murcia, Spain

Locations

  • Spain

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • N/A

Biomarkers

  • Circulating tumor cells

Drug/Treatment

  • Enzalutamide

Outcome

  • N/A

Study Design

  • Multicenteric

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved